An ABM Playbook for Targeting Hospital Systems With Multiple Decision-Makers | NPLUS Global

Most ABM frameworks were built for tech buying committees — a VP, a couple of directors, maybe procurement at the end. Hospital systems don't work that way, and treating them like a slightly bigger version of a SaaS deal is why so many "account-based" campaigns into health systems quietly stall after the first meeting. Below are the questions worth answering before you build the plan, not after.

What actually makes a hospital system's buying committee different from a typical enterprise ABM target?

The core difference isn't size, it's structural fragmentation with overlapping authority. A single health system can have a service-line VP who wants your solution, a CMIO who has veto power over anything touching clinical workflow, a supply chain or value analysis committee that has to approve spend regardless of who wants it, and a system-level IT security team that can kill a deal months in without ever meeting sales. None of these people report to each other in a clean line, and their incentives frequently conflict — the clinical champion wants speed, value analysis wants cost justification, and IT wants risk minimized. A tech ABM playbook assumes a buying committee that converges; in healthcare you're often managing a standing disagreement and trying to build enough consensus around it to get a signature.

How do you even identify who's on the committee when the org chart doesn't reflect real influence?

You start by accepting that the formal org chart is a starting hypothesis, not a map. Titles like "Director of Clinical Informatics" or "VP of Ambulatory Services" mean wildly different things depending on the system's governance model, and the people who actually gate decisions — a value analysis nurse, a physician champion with no formal authority, a regional CFO who sits above the facility CFO — rarely show up in a scraped org chart. The practical approach is layering: use firmographic and role data to build the initial hypothesis, then validate and correct it through discovery calls, deal debriefs from past health-system sales, and pattern-matching against similar systems you've sold into before. Treat the account map as a living document that gets revised every time you learn something, not a static asset built once at kickoff.

Isn't this just expensive personalization theater? Health systems run 12-18 month sales cycles and procurement is often RFP-driven anyway — does ABM actually change outcomes, or just make the pitch deck feel more sophisticated?

That's a fair challenge, and the honest answer is: ABM doesn't shorten the RFP-driven parts of the cycle, and if your definition of success is "close faster," you'll be disappointed. What it does change is who's already aligned by the time the RFP exists — because in most health systems, the RFP is a formalization of a decision that's already been shaped informally by the clinical champion, value analysis, and IT security over the preceding year. If your ABM motion hasn't reached those people with relevant, role-specific information before the formal process starts, you're responding to a document written with a competitor's fingerprints on it. The ROI isn't in cycle-time compression; it's in whether you're inside the room when the requirements get written, or reading them cold like everyone else.

Hospital systems have both centralized system-level purchasing and decentralized facility-level buying — how should account tiers reflect that?

This is where a lot of ABM programs get the segmentation backwards by treating "health system" as one account when it's really a portfolio of semi-autonomous buying units under a shared brand and, sometimes, a shared EHR or GPO contract. A workable model tiers accounts by actual decision authority rather than logo size: system-level accounts where a centralized committee governs most categories, hybrid accounts where corporate sets policy but facilities execute procurement within it, and facility-level accounts that operate almost independently despite being part of a larger name. Applying a single messaging and outreach cadence across all three wastes effort — a pitch built for a system CIO doesn't land with a facility director who's never spoken to corporate IT about a purchase in years. The tiering decision should come before content and cadence planning, not after, because it determines whether you're running one campaign or three coordinated ones.

What's the actual failure mode with contact and org data in this space, and why does it matter more here than in other B2B verticals?

Health systems churn structurally more than most industries — physician and executive turnover is high, M&A and system affiliations reshuffle reporting lines every year or two, and service-line reorganizations happen quietly without press releases. The failure mode isn't usually "the data is wrong," it's "the data was right eight months ago and nobody flagged that it changed," which means your ABM sequence is nurturing a contact who left, or worse, is now at a competing system with knowledge of your pricing. This is a place where working with a data partner that understands healthcare organizational churn specifically — not just general B2B contact hygiene — actually matters; NPLUS Global's work in this space, for instance, treats org-chart volatility as a recurring maintenance problem rather than a one-time data pull. Whatever the source, build a refresh cadence into the campaign itself, because stale mapping quietly degrades an ABM program long before anyone notices the pipeline numbers softening.

How should you actually measure whether a multi-stakeholder ABM motion into a health system is working, without falling back on vanity engagement metrics?

Engagement metrics like email opens or ad impressions tell you almost nothing in a 12-18 month cycle with a dozen stakeholders — you need signals tied to committee progression instead. Track whether you're getting introduced to new roles you hadn't previously reached (a sign you're expanding within the account, not just repeating outreach to the same three people), whether clinical or IT stakeholders are engaging with different content than economic buyers are, and whether deal velocity changes when specific roles get activated versus when they don't. The more useful long-cycle metric is often "committee coverage density" — what percentage of the mapped decision-making roles have had a real interaction with your team — compared against how that density correlated with win rates in past health-system deals. It's slower and less satisfying than a dashboard full of green arrows, but it's the version of measurement that actually reflects how these deals get won or lost.